At Dynacare, our vision is to be Canada’s health and wellness solutions leader.
Effective October 4th, 2021, Dynacare will make changes to the reporting of urinary protein electrophoresis test.
Currently, the presence of M-protein in urine samples is reported, but a quantitative estimation of the amount of the M-protein is not provided. Both the percentage and absolute quantity (g/d) of M-protein in total urinary protein will be reported for 24-hr urine samples. Only the percentage of M-protein in the total urinary protein will be reported for random urine samples.
This change to reporting is to align with the inclusion of urinary M-protein quantitation in the updated clinical guidelines from the International Myeloma Working Group.1,2 Urinary M-protein quantitation should be used in the diagnosis of light-chain monoclonal gammopathy of undetermined significance (MGUS), and for evaluating response in multiple myeloma.
If you have any questions or require further information, please contact:
Hui Li, PhD, FCACB, DABCC, FACB
800.668.2714 x 5208
Partner Update - Changes to Urinary Protein Electrophoresis Reporting